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Key Points
 Parmodulins are a new class of PAR1 inhibitors that target the cytosolic
face of PAR1 to block signaling through Gαq, but not Gα12/13.
 Unlike vorapaxar, which causes endothelial injury, parmodulins
selectively block proinflammatory, but not cytoprotective, signaling.
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Abstract: Protease-activated receptor-1 (PAR1) couples the coagulation
cascade to platelet activation during myocardial infarction and to endothelial
inflammation during sepsis. This receptor demonstrates marked signaling
bias. Its activation by thrombin stimulates prothrombotic and
proinflammatory signaling, whereas its activation by activated protein C (APC)
stimulates cytoprotective and antiinflammatory signaling. A challenge in
developing PAR1-targeted therapies is to inhibit detrimental signaling while
sparing beneficial pathways. We now characterize a novel class of structurally
unrelated small-molecule PAR1 antagonists, termed parmodulins, and
compare the activity of these compounds to previously characterized
compounds that act at the PAR1 ligand–binding site. We find that parmodulins
target the cytoplasmic face of PAR1 without modifying the ligand-binding site,
blocking signaling through Gαq but not Gα13 in vitro and thrombus formation
in vivo. In endothelium, parmodulins inhibit prothrombotic and
proinflammatory signaling without blocking APC-mediated pathways or
inducing endothelial injury. In contrast, orthosteric PAR1 antagonists such as
vorapaxar inhibit all signaling downstream of PAR1. Furthermore, exposure of
endothelial cells to nanomolar concentrations of vorapaxar induces endothelial
cell barrier dysfunction and apoptosis. These studies demonstrate how
functionally selective antagonism can be achieved by targeting the
cytoplasmic face of a G-protein–coupled receptor to selectively block
pathologic signaling while preserving cytoprotective pathways.

Introduction
Protease-activated receptor 1 (PAR1) is a widely expressed Gprotein–coupled receptor (GPCR) that detects proteases in the
extracellular environment with high sensitivity. It is activated by an
intramolecular signaling mechanism whereby cleavage of the Nterminus of the receptor by a protease exposes a tethered ligand that
interacts with a shallow, extended binding site on the extracellular face
of the receptor.1 The effective concentration of the tethered ligand is
high, owing to entropy considerations and has been estimated to be
∼400 μM, making the ligand difficult to block using soluble
antagonists.1 The molecular pharmacology of PAR1 is further
complicated by the fact that PAR1 is a functionally-biased receptor that
activates different signaling cascades depending on the proteases by
which it is cleaved and the cell type on which it resides. The signaling
bias of PAR1 is particularly prominent in endothelial cells, in which
activation of PAR1 by thrombin or metalloproteases results in loss of
barrier function and apoptosis,2-4 whereas activation of PAR1 by
activated protein C (APC) is protective against loss of barrier function
and apoptosis induced by chemokines and toxins.5-11
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PAR1 has been the focus of several drug development
programs, owing to the importance of platelet PAR1 in myocardial
infarction and stroke. Two fundamental problems in developing smallmolecule inhibitors of PAR1 have been (1) identifying compounds
capable of competing with the tethered ligand at its binding site and
(2) blocking the detrimental effects of PAR1 signaling while preserving
its cytoprotective signaling. Several small-molecule inhibitors of PAR1
that effectively compete with the ligand binding site have been
developed.12-16 The most well-characterized of these orthosteric
inhibitors is vorapaxar, which recently received Food and Drug
Administration approval for the prevention of thrombotic
cardiovascular events in high-risk patients. Vorapaxar has been
evaluated in 2 large, randomized phase 3 clinical studies in the
settings of acute coronary syndromes (TRACER)17 and in secondary
prevention of atherothrombotic events (TRA-2P).18 Its use was
associated with decreased cardiovascular death or ischemic events in
the secondary prevention trial.18 However, vorapaxar recipients had a
significantly increased incidence of major bleeding, including
intracranial hemorrhage, in both studies. Meta-analyses of clinical
trials evaluating vorapaxar and a second orthosteric PAR1 antagonist,
atopaxar, confirm an association of these inhibitors with bleeding
risk.19,20
Like vorapaxar and atopaxar, the vast majority of smallmolecule GPCR antagonists in clinical use target the ligand-binding
pocket. However, selective control of downstream G-protein–coupled
signaling pathways may be achieved by targeting alternative binding
sites.21 This approach is particularly relevant for GPCRs such as PAR1,
which mediates signaling through pathologic and protective pathways
that are distinct and separable. We now describe a new class of PAR1
antagonists termed parmodulins. These compounds act at the cytosolic
face of PAR1 and selectively inhibit some, but not all, Gα-mediated
signaling cascades in platelets and endothelial cells. We find that
orthosteric antagonists such as vorapaxar inhibit cytoprotective
signaling and elicit endothelial injury, even at nanomolar
concentrations achieved in plasma with dosing regimens described in
clinical studies. In contrast, parmodulins inhibit proinflammatory
signaling without blocking APC-mediated protective effects or eliciting
apoptosis. These studies demonstrate that functionally selective
compounds that target the cytosolic surface represent an important
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alternative to orthosteric antagonists for GPCRs with functional
signaling bias.

Methods
Reagents and compounds
Parmodulins were either synthesized at the Broad Institute or
purchased from ChemBridge. Vorapaxar and atopaxar were obtained
from Axon Medchem BV. SCH79797 and probenecid were obtained
from Tocris. The PAR1 agonist SFLLRN, the PAR4 agonist AYPGKF, and
BMS-200261 were obtained from Sigma-Aldrich. Fura-2 was obtained
from Life Technologies. Tissue-culture reagents were obtained from
Lonza. COS-7 cells, human umbilical vein endothelial cells (HUVECs),
and human microvascular endothelial cells (HMVECs) were obtained
from ATCC. High-affinity thrombin-receptor–activating peptide
(haTRAP, Ala-Phe[p-F]-Arg-ChA-HArg-[(3)H]Tyr-NH[2])14 was
synthesized by the Tufts Analytical Core Facility. Human APC was
obtained from Haematological Technologies. Radiolabeled [3H]haTRAP
was obtained from PerkinElmer, Inc. Glass microfiber filters were
purchased from Whatman. Rat anti-mouse GPIbβ antibody conjugated
to DyLight 649 was obtained from Emfret.

PAR receptor constructs
AP-PAR1 and AP-PAR4 constructs used for transfection were a
generous gift from Dr Shaun R. Coughlin, University of California–San
Francisco. A construct encoding for a PAR1 ΔH8 mutant, in which
amino acid residues S376-L386 are replaced with an A-A-A linker, was a
generous gift of Dr. Athan Kuliopulos, Sackler School of Graduate
Biomedical Sciences, Tufts University. A detailed description of
chimeric construct generation and expression in COS-7 cells is
provided in the supplemental Methods, available on the Blood Web
site.

Ca2+ flux measurements
Ca2+ flux was evaluated using fluorometry in COS-7 cells
expressing human PAR1, PAR4, PAR1:PAR4 chimeras, the ΔH8 PAR1
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mutant, or washed platelets. Detailed methods are provided in the
supplemental Methods.

Platelet aggregation
Aggregation of platelet-rich plasma or washed platelets was
initiated by the indicated concentrations of agonists and measured
using a ChronoLog 680 Aggregation System as described previously.22
Experiments using epinephrine were performed in the presence of 50
U/mL hirudin to prevent thrombin formation. Parmodulins were used
at the lowest concentration, resulting in >90% inhibition of the
aggregation of washed platelets in response to 5 μM SFLLRN. Studies
assessing reversibility of inhibition are described in the supplemental
Methods.

RhoA-GTP assay
Washed platelets (2 × 108/mL in HEPES-Tyrode buffer) or
HUVECs plated in 6-well platelets were incubated with the indicated
parmodulins or orthosteric inhibitors and then activated with 10 μM
SFLLRN for 1 minutes before lysis. Five μL lysate was kept for analysis
of total protein expression and the remaining lysate used to precipitate
GTP-bound protein using agarose beads conjugated to GST-RhotekinRBD for RhoA (Cytoskeleton). Total and precipitated GTPase protein
was measured by immunoblot analysis and visualized using enhanced
chemoluminescence. Gels representative of 3 to 5 trials for each
condition are presented.

Equilibrium-binding studies
Platelet membranes were prepared from outdated human donor
platelets supplied by the blood bank at Beth Israel Deaconess Medical
Center and BloodSource as previously described.22 Binding studies
were performed in triplicate in 1.5 mL Eppendorf tubes at a final assay
volume of 200 μL. Bovine serum albumin (0.1%) was included in the
incubation buffer and filter plates were presoaked in 0.1%
polyethyleneimine to reduce binding of [3H]haTRAP to tubes and
pipette tips. [3H]haTRAP (25 nM) was mixed with the indicated
concentration of compounds or vehicle in binding buffer (50 mM TrisBlood, Vol. 125, No. 12 (March 19, 2015): pg. 1976-1985. DOI. This article is © American Society of Hematology and
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HCl, pH 7.5, 10 mM MgCl2, 1 mM ethylene glycol tetraacetic acid
(EGTA), 0.1% bovine serum albumin). The reaction was initiated with
the addition of membranes (0.4 mg/mL) to the reaction mixture. The
tubes were capped and mixed gently in a water-bath shaker for 1 hour
at room temperature. The reaction was stopped via vacuum filtration
using Whatman GF/B filters presoaked for at least 1 hour in 0.1%
polyethyleneimine. Filters were rapidly washed 4 times with 300 μL of
ice-cold 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA. The filters
were then added to individual scintillation vials. Five mL of Ultima Gold
Scintillation cocktail was added to each vial, and the plates were
counted in a scintillation counter. Binding of [3H]haTRAP to platelet
membranes was analyzed using nonlinear regression to obtain
apparent Kd and βmax.

Apoptosis assay
The detection of apoptotic HUVECs was analyzed using a
modified version of the Vybrant apoptosis kit #4 (Life Technologies).
HUVECs were seeded onto glass coverslips in 24-well plates and grown
until they were confluent. Cells were treated with the indicated
concentrations of antagonists followed by the addition of Yo-Pro-1 as
directed by the manufacturer. After Yo-Pro-1 labeling, cells were fixed
with 4% paraformaldehyde in phosphate-buffered saline. Cells were
washed in phosphate-buffered saline and subsequently stained with
300 nM 4,6 diamidino-2-phenylindole (DAPI). Coverslips were
mounted onto glass slides with Aqua Poly/Mount (Polysciences, Inc.)
and allowed to cure overnight. Micrographs were captured using a 20X
Olympus Plan Achromat Objective, 0.4 NA, 1.2 mm WD fitted onto an
Olympus Bx62 microscope with attached Hamamatsu Orca AG camera.
The microscope, filters, and camera were controlled by Slidebook.
Images were exported into ImageJ for analysis of cells stained with
Yo-Pro-1 divided by the total cell count. Data were expressed as %
apoptotic cells.

Endothelial exocytosis assays
HUVECs or human aortic endothelial cells were seeded in 6-well
plates and grown until they were confluent. Cells were washed twice
and incubated in EBM2 serum-free medium for 2 hours at 37°C. After
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preincubation of HUVECs with vorapaxar (0.3 µM), parmodulin 2 (10
µM) or vehicle (dimethyl sulfoxide) for 30 minutes, cells were exposed
to buffer or SFLLRN (10 µM) for 1 hour at 37°C. The supernatants
from endothelial cells were collected and centrifuged for 3 minutes at
1500g to remove cell debris. von Willebrand factor (VWF) antigen
levels were quantified using a sandwich enzyme-linked immunosorbent
assay (ELISA) as described previously.23

Transendothelial electric resistance
Transendothelial electric resistance (TER) was measured using
an electric cell-substrate impedance sensing system (Applied
BioPhysics Inc.). Values were pooled at discrete time points and were
either plotted vs time or reported as bar graphs at the time point of
maximal response to a given stimulus, as described elsewhere in
detail.24 Each condition’s end-point resistance was divided by its
starting resistance to give the normalized TER. Confluence was
determined by the monolayer achieving manufacturer-recommended
electric criteria (resistance >1800 ohms and capacitance <10 nF).

Transfection of siRNA
HUVECs were grown on glass coverslips until they were 70%
confluent. Transfections were performed with Lipofectamine RNAiMAX
(Life Technologies) according to the manufacturer’s instructions.
Validated siRNA for PAR1 was purchased from Life Technologies (Cat.
#4390824). Confirmation of knockdown was completed using TaqMan
gene expression assay (ID #Hs00169258_m1) according to the
manufacturer’s instructions. Isolation of total RNA was completed
using the PureLink RNA mini kit (Life Technologies) and cDNA
synthesis was completed using the Superscript Vilo cDNA synthesis kit
(Life Technologies) according to the manufacturer’s instructions.

Laser-induced injury
The effect of parmodulin 2 on thrombus formation was
evaluated by monitoring platelet accumulation after laser-induced
injury of cremaster arterioles as previously described19 and detailed
the supplemental Methods.
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Tail-tip amputation assay
Hemostasis was evaluated using a tail-tip amputation assay as
detailed in the supplemental Methods.

Results
Identification of 2 classes of PAR1 antagonists
In performing high-throughput screening for inhibitors of
platelet activation induced by the PAR1-activating peptide, SFLLRN, we
previously identified 4 structurally unrelated inhibitors of SFLLRNinduced dense granule release (Figure 1A).22,25-27 We compared the
activity of these compounds with that of orthosteric antagonists of
PAR1. Orthosteric antagonists included vorapaxar, atopaxar,
SCH79797, and BMS-200261 (Figure 1B). To determine which PAR1
inhibitors targeted extracellular binding sites and which targeted the
cytosolic face of PAR1, we evaluated their activity in COS-7 cells
expressing either wild-type human PAR1 or a PAR1/PAR4CT chimera
consisting of amino acids 1 to 365 of PAR1 and 334 to 385 of the Cterminus of PAR4. The PAR4 cytoplasmic tail was used because none of
these compounds inhibits platelet activation mediated through
PAR4.22,25-27 Expression levels of receptors were quantified using an
alkaline phosphatase assay (supplemental Figure 1). All compounds
inhibited [Ca2+]i flux stimulated by the PAR1-specific agonist SFLLRN
when tested in COS-7 cells overexpressing PAR1 (Figure 1C). All
orthosteric antagonists also inhibited activation of the PAR1/PAR4CT
chimera (Figure 1D). In contrast, none of the compounds that we
identified in our screens inhibited activation through the cytoplasmic
tail chimera (Figure 1D). We termed these novel PAR1 inhibitors
parmodulins.
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Figure 1: Identification of 2 classes of PAR1 antagonists. (A) Structure of
parmodulins. (B) Structure of orthosteric inhibitors. The effect of vehicle (N/A), 10 μM
parmodulin 1 (PM1), 3 μM parmodulin 2 (PM2), 10 μM parmodulin 3 (PM3), 10 μM
parmodulin 4 (PM4), 0.3 μM vorapaxar (V), 0.3 μM atopaxar (A), 3 μM SCH79797 (S),
or 3 μM BMS-200261 (B) on SFLLRN-induced [Ca2+]i was evaluated in COS-7
transfected with (C) PAR1 or (D) PAR1/PAR4CT, in which the cytoplasmic tail of PAR1
(white) is replaced with that of PAR4 (gray). Increase in [Ca2+]i flux after stimulation
with 5 μM SFLLRN was evaluated. Data are presented as means ± standard error of
the mean (SEM) (n = 6).

Mechanism of action of parmodulins
Orthosteric PAR1 inhibitors and parmodulins were subsequently
tested in platelets. All compounds blocked SFLLRN-induced platelet
aggregation (Figure 2A-B). Inhibition of platelet aggregation by
parmodulins was reversed after platelets were washed (Figure 2A),
whereas washing did not reverse inhibition of platelet aggregation by
orthosteric inhibitors (Figure 2B). Aggregometry tracings
demonstrated that parmodulins failed to inhibit platelet shape change
even at concentrations that totally blocked platelet aggregation,
whereas orthosteric inhibitors blocked both shape change and
aggregation (supplemental Figure 2A). To evaluate the activity of PAR1
antagonists on downstream signaling, we tested their effect on Gαqmediated [Ca2+]i flux, which is required for aggregation,28 and on Gα13mediated activation of RhoA, which is required for shape change.29 All
compounds inhibited SFLLRN-stimulated [Ca2+]i flux (Figure 2C),
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indicating inhibition of Gαq-mediated signaling. However, although
orthosteric inhibitors completely blocked activation of Gα13-mediated
activation of RhoA, PAR1-mediated GDP/GTP exchange at RhoA could
be detected in the presence of parmodulins (Figure 2D). Densitometry
of multiple samples confirmed this result (supplemental Figure 2B).
These studies demonstrate that parmodulins inhibit PAR1 activation via
a mechanism that is distinct from that of orthosteric inhibitors and
involves selective inhibition of Gα subunits.

Figure 2: Parmodulins inhibit signaling mediated through platelet Gαq, but not
Gα13. Platelets were incubated in the presence (black line) or absence (dark gray line)
of (A) 10 μM parmodulin 1 (PM1), 3 μM parmodulin 2 (PM2), 10 μM parmodulin 3
(PM3), or 10 μM parmodulin 4 (PM4); or (B) 0.3 μM vorapaxar, 0.3 μM atopaxar, 1 μM
SCH79797, or 3 μM BMS-200261, and subsequently stimulated with 5 μM SFLLRN.
Reversibility was assessed after washing platelets incubated with PAR1 antagonists
and exposing them to 5 μM SFLLRN (light gray line). (C) Platelets were incubated with
parmodulins or orthosteric PAR1 agonists as described in (A) and (B), respectively,
and evaluated for [Ca2+]i flux after incubation with 5 μM SFLLRN. Data are presented
as means ± SEM (n = 4). (D) Platelets were incubated with the indicated PAR1
antagonists at the concentrations described in the previous legends and subsequently
exposed to vehicle (–) or 10 μM SFLLRN (+). Activation of RhoA after exposure to
SFLLRN was evaluated.

The observation that parmodulins act by a common mechanism
involving the cytosolic face of PAR1 to selectively inhibit downstream
signaling was unexpected because these compounds were all identified
in a screen of ligand-induced activation.22,25,26 Equilibrium-binding
studies were therefore performed using parmodulins 1 and 2 to
determine whether they affect agonist association with the ligand
binding site of PAR1. [3H]haTRAP, a high-affinity PAR1 orthosteric
ligand, was used to monitor binding to PAR1 on platelet membranes.14
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[3H]haTRAP bound platelet membranes with a Kd of 6.87 nM ± 0.9 and
a Bmax of 7.73 ± 0.47 pmol/mg. Incubation of platelet membranes with
parmodulin 1 or parmodulin 2 did not significantly affect binding of
[3H]haTRAP to platelet membranes (Figure 3A), consistent with
experiments demonstrating activity at the intracellular face of PAR1. In
contrast, the orthosteric inhibitor SCH79797 (1 μM) blocked binding of
[3H]haTRAP (Figure 3A). These studies support the hypothesis that
parmodulin 1 and parmodulin 2 act outside the ligand-binding site
without substantially altering the PAR1 ligand–binding site.

Figure 3: Parmodulins bind outside the ligand-binding pocket and act at the
intracellular face of PAR1. (A) Equilibrium radioligand-binding studies were
performed as described in “Methods.” The effect of vehicle (closed triangles),
parmodulin 1 (open diamonds), parmodulin 2 (closed squares), and SCH79797 (open
circles) on bound (B) and free (F) [3H]TRAP after incubation with platelet membranes
was evaluated. The effect of vehicle (N/A), 10 μM parmodulin 1 (PM1), 3 μM
parmodulin 2 (PM2), and 1 μM SCH79797 (S) on agonist-induced [Ca2+]i flux was
evaluated in COS-7 transfected with (B) wild-type (WT) PAR1, (C) WT PAR4, (D) the
ΔH8 PAR1 mutant, (E) a chimeric PAR1 in which il2 was replaced with il2 of PAR4, and
(F) a chimeric PAR1 in which il3 was replaced with il3 of PAR4. [Ca2+]i flux was
evaluated after stimulation with either 5 μM SFLLRN (B,D-F) or 300 μM AYPGKF (C).
Data are presented as means ± SEM (n = 3-6). Results were analyzed using a
Bonferroni multiple comparison test as described in supplemental Table 1 (*P < .05).

To better define the molecular basis of the effect of parmodulins
at PAR1, their activity was evaluated in studies using mutant PAR1 and
PAR1/PAR4 chimeric receptors (see supplemental Figure 1 for receptor
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expression levels). Parmodulin 1, parmodulin 2, and the orthosteric
inhibitor SCH79797 blocked [Ca2+]i flux stimulated by SFLLRN when
tested in COS-7 cells overexpressing PAR1 (Figure 3B), but they failed
to block activation induced by the PAR4-specific agonist AYPGKF in
COS-7 cells overexpressing PAR4 (Figure 3C and supplemental Table
1). To assess the role of helix 8 in parmodulin activity, a PAR1 mutant
in which residues 376 to 386 had been replaced with 3 alanine
residues (ΔH8 PAR1) was tested.30 Neither parmodulin 1 nor
parmodulin 2 significantly blocked activation of the ΔH8 PAR1 mutant
(Figure 3D and supplemental Table 1). In contrast, SCH79797
inhibited this mutant as effectively as it inhibited wild-type PAR1.
Activation of a chimera in which intracellular loop 2 of PAR1 was
replaced by that of PAR4 (PAR1/PAR4 il2) was significantly inhibited by
parmodulins (Figure 3E and supplemental Table 1). Yet parmodulins
did not inhibit activation of a chimera in which intracellular loop 3 of
PAR1 was replaced by that of PAR4 (PAR1/PAR4 il3; Figure 3F and
supplemental Table 1), implicating intracellular loop 3 in parmodulin
activity. SCH79797 inhibited activation-induced [Ca2+]i flux in both
intracellular loop chimeras effectively (Figure 3E-F). These studies
indicate a role for il3 and helix 8 in conferring sensitivity to these two
structurally unrelated parmodulins.

Parmodulins demonstrate selective antagonism in
endothelial cells
Activation of PAR1 by thrombin or SFLLRN stimulates a dramatic
phenotypic change in endothelial cells characterized by exocytosis, loss
of barrier function, and contraction. We compared the ability of
parmodulins and orthosteric inhibitors to block PAR1-mediated
proinflammatory signaling in endothelial cells. All PAR1 antagonists
blocked PAR1-stimulated Gαq-mediated activation as detected by
monitoring [Ca2+]i (Figure 4A-B). The potency of inhibition of
endothelial-cell PAR1 was roughly equivalent to the inhibition of
platelet PAR1.12-16,22,25-27 Parmodulin 2 was the most potent and
selective parmodulin and demonstrated relatively little off-target
activity when tested in GPCR profiling studies (supplemental Figure
3A). In addition, selectivity was evaluated in endothelial cells, in which
parmodulin 2 inhibited PAR1-mediated secretion of VWF, but not
secretion induced by histamine, DDAVP, epinephrine, or PMA
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(supplemental Figure 3B). Inhibition of PAR1 signaling in endothelial
cells was reversible (supplemental Figure 4A) and selective for Gαq
over Gα12/13 (Figure 4A and supplemental Figure 4B). Parmodulin 2 and
vorapaxar inhibited PAR1-mediated endothelial cell Weibel-Palade body
exocytosis, as indicated by secretion of VWF (Figure 4C and
supplemental Figure 4C). Parmodulin 2 and vorapaxar also inhibited
thrombin-induced endothelial cell contraction (Figure 4D). Further,
parmodulin 2 and vorapaxar inhibited PAR1-mediated loss of barrier
function, as evidenced by a transendothelial cell resistance assay
(Figure 4E-F).

Figure 4: Parmodulin 2 and vorapaxar inhibit proinflammatory signaling in
endothelial cells. HUVECs were incubated with the indicated concentrations of (A)
parmodulins or (B) orthosteric inhibitors for 30 minutes before exposure to SFLLRN.
Increase in [Ca2+]i flux after stimulation with 5 μM SFLLRN was evaluated and
compared with vehicle controls that were not exposed to PAR1 antagonists. Data are
presented as means ± SEM (n = 3-6). (C) HUVECs were incubated with either 3 μM
parmodulin 2 (PM2) or 0.3 μM vorapaxar before exposure to vehicle (black) or SFLLRN
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(red). Release of von Willebrand factor (VWF) into supernatants was quantified by
ELISA. Data are presented as means ± SEM (n = 4). ***P < .001. (D)
Immunofluorescence microscopy of HUVECs incubated with vehicle, parmodulin 2, or
vorapaxar, exposed to buffer or 1 U/ml thrombin, and subsequently stained with PEphalloidin and DAPI. (E) Representative tracings of real-time monitoring of
transendothelial electric resistance (TER) of HMVECs incubated with vehicle, 10 μM
parmodulin 2, or 0.3 μM vorapaxar and subsequently exposed to SFLLRN (arrow). (F)
Quantification of inhibition of SFLLRN- and thrombin-induced barrier dysfunction in
HMVECs by parmodulin 2 and vorapaxar. *P < .05, **P < .01, ***P < .001.

In contrast to the proinflammatory signaling elicited by
thrombin, cleavage of endothelial cell PAR1 by APC results in a
cytoprotective program that prevents barrier dysfunction, exocytosis,
and apoptosis induced by chemokines such as tumor necrosis factor-α
(TNF-α) or toxins.5-8,31,32 A potential liability of inhibition at PAR1 is
interference with cytoprotective endothelial signaling stimulated by
APC. We compared the ability of orthosteric inhibitors and parmodulins
to block APC-mediated cytoprotection from TNF-α–induced apoptosis.
Application of APC before TNF-α exposure protected endothelial cells
from TNF-α–induced apoptosis (Figure 5A). Knockdown of PAR1 using
PAR1-specific siRNA reversed the antiapoptotic effect of APC,
confirming that APC acts through PAR1 (Figure 5A). In subsequent
studies, endothelial cells were exposed to either PM2 or vorapaxar
before incubation with APC. Cells were then exposed to TNF-α to
determine whether APC-mediated protection from apoptosis was
inhibited. Endothelial cells exposed to vorapaxar phenocopied cells in
which PAR1 had been knocked down, demonstrating that vorapaxar
blocks APC-mediated protection from apoptosis (Figure 5B). In
contrast, parmodulin 2 did not block APC-mediated protection from
apoptosis (Figure 5B). These results demonstrate that parmodulins
interfere with thrombin-induced endothelial stimulation without
blocking APC-induced protection from apoptosis.
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Figure 5: Vorapaxar, but not parmodulin 2, blocks APC-mediated
cytoprotection in endothelial cells. (A) Mock-transfected and PAR1 siRNA–
transfected (siPAR1) HUVECs were incubated in the presence of buffer (N/A) or APC
before exposure to vehicle or TNF-α. Incubation with APC inhibits apoptosis induced by
TNF-α in mock-transfected HUVECs, but not cells in which PAR1 has been knocked
down. (B) Endothelial cells were incubated in the presence of vehicle (white), 10 μM
parmodulin 2 (black), or 0.3 μM vorapaxar (gray) for 30 minutes. Samples were then
exposed to either buffer or APC for 4 hours. Indicated samples were subsequently
stimulated with TNF-α and analyzed for apoptosis. Data are presented as means ±
SEM (n = 5). *P < .05, **P < .01.

Vorapaxar, but not parmodulin 2, induces endothelial
cell injury
While evaluating the effect of vorapaxar on endothelial cell
phenotypes, we observed that longer incubations with vorapaxar
induced apoptosis (Figure 6A). A 24-hour exposure to vorapaxar
induced endothelial cell apoptosis in a dose-dependent manner, with
significant apoptosis occurring at 300 nM (Figure 6B). Increasing the
length of exposure increased the sensitivity of endothelial cells to
vorapaxar such that after 48 hours, significant apoptosis was observed
at 100 nM (Figure 6B). These concentrations are in the range of
predicted plasma concentrations achieved with the dosing regimens
used in the TRACER and TRA-2P studies.17,18 Similarly, atopaxar,
SCH79797, and BMS-200261 all induced apoptosis in endothelial cells
(supplemental Figure 5). In contrast, no significant increase in
apoptosis was observed when endothelial cells were incubated with
parmodulin 2 at concentrations as high as 30 μM (Figure 6A-B) or
hirudin (not shown).
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Figure 6: Vorapaxar, but not parmodulin 2, induces endothelial dysfunction
upon prolonged exposures. (A) HUVECs were exposed to vehicle alone, 10 μM
parmodulin 2, or 0.3 μM vorapaxar, as indicated, for 48 hours and subsequently
stained for apoptosis using YO-PRO-1. (B) HUVECs were incubated with the indicated
concentrations of either vorapaxar (blue) or parmodulin 2 (red) for either 24 hours
(solid lines) or 48 hours (dashed lines) and assayed for apoptosis. Data are presented
as means ± SEM (n = 5). (C) Mock-transfected (mock) and PAR1 siRNA–transfected
(siPAR1) HUVECs were incubated with either vehicle (black) or 0.3 μM vorapaxar
(blue) for either 24 or 48 hours. Samples were subsequently assayed for apoptosis. In
each condition, addition of vorapaxar led to a significant increase in apoptosis
compared with the unexposed sample (P < .001). Knockdown of PAR1 also increased
apoptosis. ***P < .001. Data are presented as means ± SEM (n = 5). (D) HMVEC
barrier function was continuously monitored by transendothelial resistance for 24
hours after exposure to either 10 μM parmodulin 2 (red) or 0.3 μM vorapaxar (blue).
***P < .001.

PAR1 antagonist–induced endothelial apoptosis could be caused
by a biased agonist effect of inhibitors that act at the ligand-binding
site. Alternatively, constitutive PAR1 activity could be important for
endothelial cell survival33,34 and PAR1 blockade could result in
apoptosis. To distinguish between these 2 possibilities, we evaluated
the effect of long-term vorapaxar exposure on endothelial cell
apoptosis after knockdown of PAR1. Transfection with PAR1-targeted
siRNA resulted in >90% knockdown. Incubation of PAR1 siRNAtransfected cells with 300 nM vorapaxar stimulated increased
apoptosis compared with incubation with mock-transfected cells at
both 24 and 48 hours (Figure 6C). In addition, there was significant
apoptosis in the absence of vorapaxar at 48 hours. Endothelial cell
apoptosis after PAR1 knockdown and 48-hour exposure to 1 or 3 μM
vorapaxar could not be quantified because the cells no longer adhered
to the plate. A 24-hour incubation with vorapaxar also induced
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significant endothelial barrier dysfunction compared with parmodulin 2
(Figure 6D). These observations indicate that long-term exposure to
vorapaxar, but not parmodulin 2, elicits endothelial cell injury.

Effect of parmodulin 2 on thrombosis and hemostasis
PAR inhibition impairs thrombus formation in both animal
models and clinical studies but is associated with bleeding.17-20 We
therefore studied parmodulin 2 in assays of both thrombosis and
hemostasis. When tested in a murine model in which thrombosis is
elicited by laser-induced injury of cremaster arterioles, parmodulin 2
(5 mg/kg) reduced platelet accumulation during thrombus formation
by 73% (Figure 7A-B). Because PAR4 is the dominant PAR on mouse
platelets, we determined whether parmodulin 2 inhibited aggregation
induced through murine PAR4. Previous studies demonstrated that
parmodulin 1 interacts with a limited number of GPCRs, including
murine PAR4, that have common features at helix 8.30 These features
include a predicted ionic interaction between position 1 of helix 8 and
the il1 loop, H-bond formation between position 3 of helix 8 and
transmembrane domain 7, a hydrophobic interaction between the
tyrosine of the NPxxY motif and an aromatic amino acid at position 2
of helix 8, and a palmitoylation site(s) at the C terminus of helix 8.22
Like parmodulin 1, parmodulin 2 blocked AYPGKF-induced aggregation
of mouse platelets (Figure 7C), but not AYPGKF-induced aggregation
of human platelets (supplemental Figure 6). Thus, parmodulin 2
inhibits activation through murine PAR4, but not human PAR4. For
hemostasis assays, parmodulin 2 (5 mg/kg) was infused into mice
before tail-tip amputation. Parmodulin 2 failed to affect bleeding times
(Figure 7D) or hemoglobin loss (Figure 7E) after transection of the tail
tip. These results show that parmodulin 2 inhibits platelet
accumulation during thrombus formation but does not affect
hemostasis in this model.
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Figure 7: Parmodulin 2 inhibits thrombus formation without prolonging
bleeding times. (A) Platelet-specific anti-GPIbβ antibody conjugated to Dylight 649
(0.1 µg/g body weight) was infused into mice. Thrombi were induced by laser injury of
cremaster arterioles before (n = 62 thrombi in 7 mice) and after (n = 54 thrombi in 7
mice) infusion of parmodulin 2 (5 mg/kg body weight). Thrombus formation was
visualized by videomicroscopy for 180 seconds after injury. Representative binarized
images of platelets at the injury site before (Control) and after parmodulin 2 infusion
(PM2) are shown. White arrowheads indicate the location of the vessel. (B) Median
integrated platelet-fluorescence intensity at the injury site in mice before (Control)
and after parmodulin 2 infusion (PM2) is plotted over time. (C) Mouse platelet
aggregation in response to 65 μM AYPGKF was evaluated after incubation with the
indicated concentrations of parmodulin 2. (D) Time to cessation of bleeding and (E)
total hemoglobin loss was measured after tail-tip amputation.

Discussion
These studies distinguish between 2 distinct classes of small
molecules capable of modulating PAR1 activity. Orthosteric PAR1
inhibitors that induce potent and effective blockade of the binding site
of the tethered ligand have been developed,17,18,35,36 and one of these,
vorapaxar, has recently been approved for secondary prevention of
cardiovascular events. As a class, these inhibitors bind tightly to PAR1.
They are inhibitory in the nanomolar range because they must
compete with a tethered ligand that has an effective concentration
estimated to be 400 μM.1 As a result of the tight binding of orthosteric
antagonists, their inhibition is not readily reversible. Blockade at the
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ligand binding site results in inhibition of all ligand-induced
downstream signaling. We now describe a second class of smallmolecule PAR1 inhibitors, the parmodulins, which distinguish
themselves on the basis of their site of action at the cytosolic face of
PAR1 and selectivity at the level of G-protein coupling. As a class,
parmodulins are less potent than orthosteric PAR1 antagonists and
demonstrate reversible antagonism. Studies in platelets show that
they inhibit PAR1-dependent Gαq-mediated elevation of [Ca2+]i flux,
but not Gα12/13-mediated signal transduction. The selectivity of
parmodulins remains to be fully defined. Our initial profiling and
functional assays (supplemental Figure 3), however, indicate that
parmodulin 2 is the most selective and parmodulins 3 and 4 are the
least selective.25-27 Nonetheless, the fact that parmodulins all
demonstrate selectivity at the level of PAR1-mediated signaling
transduction defines them as a new class of small-molecule PAR1
modulators that act at an intracellular site on PAR1.
The functional significance of these distinct modes of PAR1
inhibition is best exemplified in the effects of parmodulin 2 and
vorapaxar on endothelial cell function (supplemental Figure 7). Both
PAR1 antagonists block proinflammatory signaling in endothelial cells
(Figure 4). However, although parmodulin 2 spares APC-mediated
cytoprotection, vorapaxar blocks this pathway (Figure 5). In addition,
incubation with vorapaxar induces endothelial injury upon prolonged
exposure (Figure 6). Importantly, endothelial injury was observed at
concentrations approximating vorapaxar plasma levels achieved with
dosing protocols used in TRACER or TRA-2P, as indicated by earlier
pharmacokinetic studies.37,38 The fact that PAR1 knockdown increased
susceptibility of endothelial cells to vorapaxar-induced apoptosis
suggests that constitutive PAR1 signaling is required for endothelial
cell viability. Impaired endothelial growth and vascular formation were
observed during development in PAR1−/− mice,33,34 indicating that
PAR1 functions in endothelial cell viability in vivo. PAR1 deficiency
resulted in 50% embryonic lethality associated with diffuse
hemorrhage. Bleeding was reversed with endothelial cell–specific
expression of PAR1, raising the possibility that endothelial PAR1
functions in hemostasis.34 The dominant complication of vorapaxar in
TRACER and TRA-2P was major bleeding.19,20 Whether exposure to
vorapaxar or other orthosteric PAR1 antagonists induces endothelial
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cell injury that constitutes an additional risk factor for bleeding beyond
the antiplatelet effect requires further investigation.
Parmodulins validate the strategy of using small molecules to
target the cytosolic face of GPCRs to selectively block one downstream
signaling pathway while preserving another. GPCRs demonstrate
modularity between the extracellular (ligand-binding) and intracellular
(G-protein–binding) regions.39 Association of parmodulin 1 or 2 with
PAR1 does not dramatically affect the ligand-binding site, as indicated
by their ability to bind PAR1 without significantly modifying the binding
of [3H]ha-TRAP. Consistent with this observation, studies using
chimeric PARs indicate that interactions at the intracellular face of
PAR1 are required for parmodulin activity. Lipidated peptides modeled
after the intracellular loops of PAR1 have been developed and have
either antagonist or agonist activity at PAR1.40,41 Parmodulin activity,
however, is likely more analogous to small-molecule inhibitors directed
against the cytoplasmic face of CCR4 and CXCR2. These chemokine
inhibitors are thought to act at a binding site within or adjacent to the
G-protein–binding pocket.42-44 Mutational studies suggest that different
classes of G-proteins associate with different regions on the
cytoplasmic face of PAR1.45 Parmodulins could bind at or near the Gprotein–binding pocket and selectively compete with Gαq, but not
Gα12/13. The ability of antagonists that target an intracellular site to
selectively impair downstream G-protein signaling has not previously
been studied. Our data show that by targeting the cytosolic face of
PAR1, parmodulins inhibit PAR1-induced proinflammatory signaling in
endothelial cells without blocking APC-mediated cytoprotection
signaling through PAR1. In vivo, these compounds block arteriolar
thrombosis without increasing bleeding times after tail clip.
Parmodulins represent a prototype for the identification and
characterization of compounds that target the cytosolic face of GPCRs
to selectively inhibit coupling to some Gα subunits, but not others.
Small molecules targeting the G-protein–binding site will be useful in
dissecting the molecular determinants of GPCR–G-protein coupling and
developing new approaches to pharmacologically manipulate that
coupling. Ultimately, such compounds could be used to inhibit
pathways that mediate pathologic signaling while preserving or even
stimulating protective signaling pathways.
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